Atlas
Market PulseMovers & ShakersSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › MARKSANS

MARKSANS

Marksans Pharma Limited
Small-capPharma ↗

What the six lenses say about MARKSANS — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹335.1
2026-09-08
VWAP · 1Y anchor
₹242
+38.7% from VWAP
P/E · TTM
36.3×
TTM EPS ₹9.2
52-week range
100%
position low→high
RSI(14)
66
momentum

Own sector index

Pharma ↗
Overweight

1M

+0.4%

3M

+10.5%

1Y

+22.0%

Breadth >EMA21

56%

How MARKSANS’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
6.0
avg conviction decile
Leadership
Leader
top-decile composite in cohort
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Small-cap cohortDRaw
TechnicalD10100›

The actual numbers

Price vs VWAP (1y)+38.7%
EMA trend stackUp · 21>50>200
Price vs 200-EMA+41.7%
Price vs 50-EMA+14.7%
RSI(14)66
RS vs Nifty 500 · 3M+37.5%
RS vs sector · 3M+31.5%
52-week range100%
Volume vs 30d avg1.07×
Volume vs 60d avg1.45×
ATR(14) · volatility15.6
Bollinger width · vol contraction0.144
FundamentalD653›

The actual numbers

Return on equity (ROE)13.9%
Operating margin19.8%
Net margin14.2%
Revenue growth · YoY+12.5%
EPS growth · YoY+9.9%
Debt / equity0.11×

Full 8-quarter history in the financials table below.

ValuationD621›

The actual numbers

P/E (TTM)36.3×
TTM EPS₹9.2
52-week range100%
CatalystD744›

The actual numbers

Earnings & momentum53
Capital actions10
Governance80

Every filing in the corporate-announcements panel below.

FlowD242›

The actual numbers

Promoter holding43.9%
Delivery · 30d avg36.8%
Up/down-day asymmetry-5.0pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Small-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D10 + D2 ) ÷ 2 = 6.0(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Highest
94
Conviction score 94/100 · avg-decile strength 6.0/10
Conviction score94/100›
TechnicalD10›
FundamentalD6›
ValuationD6›
CatalystD7›
FlowD2›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-09-08.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
+3.0pp
+5.4pp
+28.1pp
+39.1pp
+98.6pp
+101.7pp
Nifty 500
Broad-market baseline
+3.0pp
+5.4pp
+27.0pp
+37.5pp
+92.9pp
+96.5pp
Sector
Own-sector index
—
—
+24.2pp
+31.5pp
+79.7pp
+75.7pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

MARKSANS daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
335.05+8.30

Relative strength

RS vs baseline · rebased to 100

MARKSANS ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
131.62+3.80

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)591642682708620720754856
↳ change QoQ—+8.7%+6.2%+3.8%-12.4%+16.1%+4.7%+13.5%
EBITDA (₹cr)143147167127100144161195
EBITDA margin24.3%22.9%24.4%17.9%16.1%20.0%21.3%22.8%
PAT (₹cr)8998105915899114149
↳ change QoQ—+9.8%+7.5%-13.4%-36.3%+70.7%+15.2%+30.7%
Net margin15.1%15.2%15.4%12.8%9.3%13.8%15.1%17.4%
EPS (₹)1.962.132.312.001.292.172.503.27
D/E————————
YoY growth · Mar '26Revenue +20.9% YoYPAT +63.7% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 1 Sep '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 26 Aug '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 20 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 13 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 12 Aug '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 12 Aug '26
    MEDIUMearnings
    Investor Presentation
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 12 Aug '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 4 Aug '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 3 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 20 Jul '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 17 Jul '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 8 Jul '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 3 Jul '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 3 Jul '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 3 Jul '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds MARKSANS

Mutual funds holding MARKSANS (9)

FundWeightAUM ₹crGrade
UTI Aggressive Hybrid Reg Gr0.55%6,760
UTI Large & Mid Cap Reg Gr0.80%6,407
UTI Small Cap Reg Gr1.45%5,263
UTI Multi Cap Reg Gr0.84%2,131
UTI Healthcare Reg Gr2.17%1,371
JM Small Cap Reg Gr1.00%868
Kotak Healthcare Reg Gr2.27%682
Old Bridge Flexi Cap Reg Gr2.37%256
Unifi Flexi Cap Reg Gr1.93%227

ETFs holding MARKSANS (0)

No tracked ETF holds MARKSANS ≥0.5%.

Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma